Literature DB >> 18245704

Mitral valve replacement in severe pulmonary arterial hypertension.

Mohammad Mubeen1, Amrendra K Singh, Surendra K Agarwal, Jeewan Pillai, Shalini Kapoor, Ashok K Srivastava.   

Abstract

The immediate postoperative hemodynamics in 43 patients with severe pulmonary arterial hypertension who underwent mitral valve replacement between January 2000 and September 2001 were studied prospectively. The mean age was 30.6 years. There was mitral stenosis in 19 (44.1%), mitral regurgitation in 9 (20.9%), and mixed lesions in 15 (34.9%). In 36 patients (83.7%, group 1) pulmonary arterial pressure was sub-systemic, with a mean of 58.1 mm Hg and pulmonary vascular resistance of 743.4 dyne x s x cm(-5). Seven patients (16.3%, group 2) had supra-systemic pulmonary arterial pressure of 83.2 mm Hg and pulmonary vascular resistance of 1,529 dyne x s x cm(-5). Lung biopsies were taken from the right lower lobe in 24 patients. Operative mortality was 5.5% in group 1 and 28.5% in group 2. After mitral valve replacement, the pulmonary arterial pressure and vascular resistance decreased significantly in group 1. In group 2, pulmonary arterial pressure decreased significantly but pulmonary vascular resistance remained elevated. Pulmonary vascular changes did not progress beyond grade III (Heath-Edwards' classification). Mitral valve replacement is safe even in the presence of severe pulmonary arterial hypertension as long as pulmonary arterial pressures are below systemic pressures. Lung biopsy did not help in identifying patients with irreversible pulmonary arterial changes.

Entities:  

Mesh:

Year:  2008        PMID: 18245704     DOI: 10.1177/021849230801600110

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  7 in total

Review 1.  Reversal of abnormal cardiac parameters following mitral valve replacement for severe mitral stenosis in relation to pulmonary artery pressure: A retrospective study of noninvasive parameters - Early and late pattern.

Authors:  Usha T Parvathy; Rajesh Rajan; Alexander Georgevich Faybushevich
Journal:  Interv Med Appl Sci       Date:  2016-06-01

2.  Prevalence and survival associated with pulmonary hypertension after mitral valve replacement: National echocardiography database of Australia study.

Authors:  Nicholas Collins; Stuart Sugito; Allan Davies; Andrew Boyle; Aaron Sverdlov; John Attia; Simon Stewart; David Playford; Geoff Strange
Journal:  Pulm Circ       Date:  2022-10-01       Impact factor: 2.886

3.  Value of pulmonary artery pressure in predicting in-hospital and one-year mortality after valve replacement surgery in middle-aged and aged patients with rheumatic mitral disease: an observational study.

Authors:  Lei Jiang; Xue-Biao Wei; Peng-Cheng He; Du Feng; Yuan-Hui Liu; Jin Liu; Ji-Yan Chen; Dan-Qing Yu; Ning Tan
Journal:  BMJ Open       Date:  2017-05-10       Impact factor: 2.692

4.  Impact of preoperative pulmonary arterial hypertension on early and late outcomes in patients undergoing valve surgery for rheumatic heart disease.

Authors:  Deepak Prakash Borde; Balaji Asegaonkar; Sujit Khade; Manish Puranik; Antony George; Shreedhar Joshi
Journal:  Indian J Anaesth       Date:  2018-12

5.  Perioperative management of a patient with double orifice mitral valve with supramitral ring with subaortic membrane with ventricular septal defect and severe pulmonary hypertension: Report of a rare case.

Authors:  Vishnu Datt; Priyanka Khurana; Saket Aggarwal; Smita Mishra; C N Sujith; Sanjula Virmani
Journal:  Ann Card Anaesth       Date:  2019 Apr-Jun

6.  Pulmonary Hypertension as a Predictor of Early Outcomes of Mitral Valve Replacement: A Study in Rheumatic Heart Disease Patients.

Authors:  Omer Farooq; Azam Jan; Usman Ghani; Usman Qazi; Waasay Hassan Khan; Sundus Alam; Muhammad Junaid Khan; Omair A Khan; Nabil I Awan; Hussain Shah
Journal:  Cureus       Date:  2021-12-01

7.  Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Perioperative management in patients with pulmonary hypertension.

Authors:  Adriano R Tonelli; Omar A Minai
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.